Medtronic announces fda approval of simplera™ cgm and global partnership with abbott

Medtronic diabetes expands cgm offerings to meet more people where they are in their diabetes journey dublin , aug. 7, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced the u.s. food and drug administration (fda) approval for its simplera™ continuous glucose monitor (cgm) — the company's first disposable, all-in-one cgm that's half the size of previous medtronic cgms. the discreet design simplifies the insertion and wear experience, eliminating the need for overtape.
MDT Ratings Summary
MDT Quant Ranking